GSK (LSE:GSK) Secures Ex China Rights To KRAS EGFR Cancer Drug

What happened: GSK (LSE:GSK) agreed an exclusive global licence with HUTCHMED for the KRAS-EGFR antibody drug conjugate HMPL-A830, excluding mainland China, Hong Kong, Macau and Taiwan. Key numbers: GSK is described as a £76.7b pharmaceuticals group. Fair value cited at £21.73. Why it matters: The deal adds a targeted oncology candidate to GSK's push into antibody drug conjugates and precision therapies. Analysts already see this area as a way to improve product mix while the Accelerate Growth cost program supports margins.

GSK (LSE:GSK) agreed an exclusive global licence with HUTCHMED for the KRAS-EGFR antibody drug conjugate HMPL-A830, excluding mainland China, Hong Kong, Macau and Taiwan.

The deal adds a targeted oncology candidate to GSK's push into antibody drug conjugates and precision therapies. Analysts already see this area as a way to improve product mix while the Accelerate Growth cost program supports margins.